GLP-1 Drug Pricing Guide: Best Prices as of April 2026
GLP-1 prices in April 2026: Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo, compounded options, India generics, and the TrumpRx and Medicare programs.
The GLP-1 pricing picture has fragmented in 2026. The same drug, semaglutide, now ranges from $14/month (Indian generic) to $1,349/month (US list price), a 96x spread. Between TrumpRx deals, manufacturer direct programs, new subscription models, and India's post-patent generic flood, the sticker price has less and less to do with what patients pay.
The bottom line for patients: If you have commercial insurance that covers GLP-1s, you can pay as little as $25/month with a manufacturer savings card, whichever drug you choose. If you are uninsured, the cheapest entry points are Foundayo at $149/mo (LillyDirect) and Ozempic at $199/mo (NovoCare intro offer). For long-term uninsured maintenance, Wegovy's 12-month subscription at $249/mo is the best deal. Medicare patients pay $50/mo through the TrumpRx program.
Below is a breakdown of every major GLP-1 drug, what you pay through each channel, and where the market is headed, with all prices current as of April 2026 and cited to primary sources. For a visual summary, see our GLP-1 Prices Infographic. For how prices have changed over time, see our GLP-1 Pricing Trends charts.
Key context: Nobody pays list price anymore. The WAC figures below (Wholesale Acquisition Cost, the manufacturer's list price) exist mainly for insurance reimbursement math and rebate talks. What matters is the self-pay, TrumpRx, and insurance copay prices, since those are what patients see at checkout. Novo Nordisk has announced WAC cuts to about $675/mo effective January 2027, which will finally bring list prices closer to reality.
Ozempic (Semaglutide Injection, for Diabetes)
Novo Nordisk's injectable semaglutide for type 2 diabetes. It comes in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses, and most commercial insurance and Medicare Part D (Medicare's prescription drug benefit) cover it for diabetes.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,027/mo | NovoCare |
| NovoCare Self-Pay | $349/mo | Novo Nordisk PR |
| New Patient Intro Offer | $199/mo | Novo Nordisk PR |
| TrumpRx / Medicare | $245/mo | AJMC |
| Commercial Insurance + Savings Card | As low as $25/mo | NovoCare |
| 2027 List Price (Announced) | $675/mo | Novo Nordisk PR |
Wegovy (Semaglutide Injection, for Obesity)
Novo Nordisk's injectable semaglutide for chronic weight management. Doses step up from 0.25 mg to 2.4 mg. In March 2026, Novo launched a first-of-its-kind multi-month subscription program.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| NovoCare Self-Pay | $499/mo | Novo Nordisk PR |
| 12-Month Subscription | $249/mo | Novo Nordisk PR |
| 6-Month Subscription | $299/mo | Novo Nordisk PR |
| 3-Month Subscription | $329/mo | Novo Nordisk PR |
| TrumpRx / Medicare | $245/mo | Pharmacy Times |
| Commercial Insurance + Savings Card | As low as $25/mo | Wegovy.com |
| 2027 List Price (Announced) | $675/mo | Novo Nordisk PR |
Wegovy Pill (Oral Semaglutide 25 mg, for Obesity)
Novo Nordisk's oral semaglutide tablet for weight management, FDA-approved in December 2025. You take it on an empty stomach with water, then wait 30 minutes before eating. Doses step up from 1.5 mg to 25 mg.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| Self-Pay (Starter Doses) | $149/mo | NovoCare Price Guide |
| Self-Pay (Maintenance Doses) | $299/mo | NovoCare Price Guide |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
Mounjaro (Tirzepatide Injection, for Diabetes)
Eli Lilly's tirzepatide for type 2 diabetes. It acts on two gut-hormone receptors, GLP-1 and GIP, and comes in doses from 2.5 mg to 15 mg. Lilly sells single-dose vials at lower prices through LillyDirect.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,080/mo | Lilly Pricing Info |
| LillyDirect Vials (Starting Dose) | $299/mo | FindHonestCare |
| LillyDirect Vials (Mid Dose) | $399/mo | FindHonestCare |
| LillyDirect Vials (Higher Doses) | $449/mo | FindHonestCare |
| TrumpRx / Medicare | $245/mo | Eli Lilly IR |
| Commercial Insurance + Savings Card | As low as $25/mo | Lilly Pricing Info |
Zepbound (Tirzepatide Injection, for Obesity)
Eli Lilly's tirzepatide for chronic weight management. It is the same molecule as Mounjaro but approved for obesity, and LillyDirect sells it at much lower self-pay prices.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,086/mo | Lilly Pricing Info |
| LillyDirect Vials (Starting Dose) | $299/mo | Eli Lilly IR |
| LillyDirect Vials (Mid Dose) | $399/mo | Eli Lilly IR |
| LillyDirect Vials (Higher Doses) | $449/mo | Eli Lilly IR |
| TrumpRx | $346/mo | AJMC |
| Medicare | $245/mo | Eli Lilly IR |
| Commercial Insurance + Savings Card | As low as $25/mo | Zepbound.com |
Foundayo (Orforglipron, Oral GLP-1 Pill for Obesity)
Eli Lilly's new oral GLP-1 pill, FDA-approved April 1, 2026 and on sale since April 9. It is the only GLP-1 pill with no food or water rules, so you can take it any time of day. Doses run from 0.8 mg to 17.2 mg.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $649/mo | GoodRx |
| LillyDirect (Starting Dose) | $149/mo | Eli Lilly PR |
| LillyDirect (Most Patients) | ~$349/mo | Drugs.com |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| Medicare Part D | $50/mo copay | Eli Lilly PR |
| Commercial Insurance + Savings Card | As low as $25/mo | Eli Lilly PR |
Third-Party Digital Pharmacies
Retail and digital health platforms are entering the GLP-1 market with bundled prices that pair provider oversight with same-day delivery. Amazon One Medical launched the broadest offer on April 21, 2026, covering Wegovy, Zepbound, and Foundayo at single price points that undercut standalone telehealth programs.
Compounded Semaglutide & Tirzepatide
Compounded versions are still sold through 503A pharmacies and some 503B outsourcing facilities despite ongoing FDA enforcement. A 503A pharmacy fills patient-specific prescriptions; a 503B facility makes larger batches. Supply has tightened and low-end prices have risen since 2024-2025, and the FDA removed semaglutide from its drug shortage list in February 2025.
| Channel | Price | Source |
|---|---|---|
| Compounded Semaglutide (Starting Dose) | $159–$199/mo | Newswire / Trinity Meds |
| Compounded Semaglutide (Higher Doses) | $299–$499/mo | Newswire / Trinity Meds |
| Compounded Tirzepatide | $229–$349/mo | HealthFactsJournal |
| Pre-Crackdown Pricing (2024) | $150–$400/mo | ArentFox Schiff |
India Generic Semaglutide (Post Patent Expiry)
Semaglutide's Indian patent expired March 20, 2026, which set off an immediate flood of 26+ branded generics from 13 companies. Prices dropped up to 90% from brand levels. These generics are sold only in India, since US patents run into the 2030s.
| Channel | Price | Source |
|---|---|---|
| Cheapest Generics (Natco, Glenmark) | $15–$21/mo | NirvanaClinics |
| Mid-Range Generics (Alkem, Zydus) | $21–$26/mo | NirvanaClinics |
| Premium Generics (Sun Pharma, Dr. Reddy's) | $36–$50/mo | Business Today India |
| Branded Ozempic (India, Post-Cut) | $67–$133/mo | Business Standard |
TrumpRx Program & Medicare Coverage
The Trump administration launched TrumpRx.gov in February 2026 as a single portal for discounted GLP-1 access. Both Lilly and Novo Nordisk agreed to Most-Favored-Nation (MFN) pricing, which ties US prices to the lowest price paid in other wealthy countries. Medicare obesity coverage starts through a bridge program in July 2026.
| Channel | Price | Source |
|---|---|---|
| Injectable GLP-1s (TrumpRx Self-Pay) | $350/mo | AJMC |
| Oral GLP-1s (TrumpRx Self-Pay) | $150/mo | AMCP |
| Medicare (All GLP-1s) | $245/mo | Pharmacy Times |
| Medicare Patient Copay | $50/mo | SavingAdvice |
| Medicare Obesity Bridge (Launches July 2026) | $50/mo copay | KFF |